Hengrui Medicine: Fluorodeoxybenzyl Phosphoric Acid Injection approved by US FDA

Haihe Pharmaceutical announced that its wholly-owned subsidiary, Haihe Pharmaceutical Co., Ltd., has obtained approval for the new drug abbreviated application for Fluorouracil Phosphate Darabin Injection reported to the US FDA. This means that Haihe Hangzhou Company can now sell this product in the US market. Fluorouracil Phosphate Darabin Injection is a nucleoside metabolic inhibitor indicated for use as a component of combination therapy for the treatment of adult B-cell chronic lymphocytic leukemia; and for the treatment of adult B-cell chronic lymphocytic leukemia patients who have failed at least one therapy containing an alkylating agent, or have disease progression during therapy.